top of page

Rubik Therapeutics Pipeline
Solid Tumor Program

Explore Rubik's oncological pipeline: proprietary surface targets across 30+ tumor types, optimized for high selectivity and therapeutic potential

fusion-medical-animation-rnr8D3FNUNY-unsplash.jpg

Multiple Proprietary Targets

  • Pipeline of over 30 selective targets

  • Targets express "oncolinkage:" tumor specific dysregulation of otherwise selectively expressed genes. 

  • Designed for high therapeutic index.

  • Top five cancers: breast, lung, prostate and pancreatic are well represented. 

  • All are proprietary to Rubik.

fusion-medical-animation-rnr8D3FNUNY-unsplash.jpg
national-cancer-institute-LnvCEXQwC-o-unsplash.jpg
national-cancer-institute-LnvCEXQwC-o-unsplash.jpg

Dual Track Therapeutic Modality

  • Normal expression profile impacts therapeutic modality choice

    • CAR-T requires highly restrictive expression in normal tissue, including lack of brain (CNS) expression.​

    • Radioligands can exploit targets expressed in the brain. 

  • Binder generation pipeline designed for CAR-T or Radioligand.​​​

© 2023 by Rubik Therapeutics. All rights reserved.

bottom of page